Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 12, Issue 4, 2010, Pages 323-333

  Aaboe, K ^a,b   Knop, F K ^a   Vilsboll T ^a   Deacon, C F ^b   Holst, J J ^b   Madsbad, S ^a   Krarup, T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

DPP 4 inhibition; Glucagon like peptide 2; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretin effect; Insulin secretion; Peptide YY; Type 2 diabetes mellitus

Indexed keywords

ARGININE; C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PEPTIDE YY; PEPTIDE YY [3-36]; PLACEBO; SITAGLIPTIN; SOMATOSTATIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CELL SECRETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77954380946     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01167.x     Document Type: Article

References (47)

1. Knop FK, Vilsboll T, Hojberg PV. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007, 56:1951-1959.
2. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non- insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
3. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose- stimulated insulin secretion -Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
4. Elahi D, oon-Dyke M. Fukagawa: The insulinotropic actions of glucose- dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. NK: Regul Pept 1994, 51:63-74.
5. Toft-Nielsen MB, Damholt MB, Madsbad S. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717-3723.
6. Hojberg PV, Zander M, Vilsboll T. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 2008, 51:632-640.
7. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002, 172:355-362.
8. Drucker DJ, Shi Q, Crivici A. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997, 15:673-677.
9. Eberlein GA, Eysselein VE, Schaeffer M. A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 1989, 10:797-803.
10. Meier JJ, Nauck MA, Pott A. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006, 130:44-54.
11. Henriksen DB, Alexandersen P, Bjarnason NH. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003, 18:2180-2189.
12. Koegler FH, Enriori PJ, Billes SK. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 2005, 54:3198-3204.
13. Ishihara A, Tanaka T, Kanatani A, Fukami T, Ihara M, Fukuroda T. A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am J Physiol 1998, 274:R1500-R1504.
14. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
15. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002, 25:S5-S20. (Suppl. 1):
16. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: diagnosis and classification of diabetes mellitus -provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
17. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 1994, 43:535-539.
18. Vilsboll T, Krarup T, Sonne J. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003, 88:2706-2713.
19. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000, 21:73-80.
20. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 1984, 9:35-46.
21. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85:3575-3581.
22. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991, 87:415-423.
23. Baldissera FGA, Holst JJ. Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 1984, 26:223-228.
24. Holst JJ, Pedersen JH, Baldissera F, Stadil F. Circulating glucagon after total pancreatectomy in man. Diabetologia 1983, 25:396-399.
25. Baldissera FG, Munoz-Perez MA, Holst JJ. Somatostatin 1-28 circulates in human plasma. Regul Pept 1983, 6:63-69.
26. Kjems LL, Christiansen E, Volund A, Bergman RN, Madsbad S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 2000, 49:580-588.
27. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
29. Vella A, Bock G, Giesler PD. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007, 56:1475-1480.
30. Vella A, Bock G, Giesler PD. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf) 2008, 69:737-744.
31. Muscelli E, Mari A, Natali A. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 2006, 291:E1144-E1150.
32. Nauck MA, El Ouaghlidi A, Gabrys B. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004, 122:209-217.
33. El-Ouaghlidi A, Rehring E, Holst JJ. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007, 92:4165-4171.
34. Herman GA, Bergman A, Stevens C. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
35. Hojberg PV, Vilsboll T, Zander M. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes. Diabet Med 2008, 25:1268-1275.
36. Migoya EM, Miller JL, Larson PJ. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetologia 2007, 50:S52.
37. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003, 114:189-196.
38. Böttcher G, Alumets J, Hσ kanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986, 13:283-291.
39. Batterham RL, Cohen MA, Ellis SM. Inhibition of food intake in obese subjects by peptide YY3- 36. N Engl J Med 2003, 349:941-948.
40. Hartmann B, Harr MB, Jeppesen PB. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000, 85:2884-2888.
41. Schuit FC, Derde MP, Pipeleers DG. Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia 1989, 32:207-212.
42. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995, 16:390-410.
43. de Heer J, Rasmussen C, Coy D, Holst J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008, 51:2263-2270.
44. Shapiro ET, Tillil H, Rubenstein AH, Polonsky KS. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab 1988, 67:1094-1099.
45. D'Alessio DA, Denney AM, Hermiller LM. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:81-88.
46. Dalla MC, Bock G, Giesler PD. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care 2009, 32:14-18.
47. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008, 11:491-499.